JSKN022

JSKN022 is an innovative bispecific antibody-drug conjugate (ADC) developed by Alphamab Oncology for the treatment of advanced malignant solid tumors. It simultaneously targets programmed cell death 1 ligand 1 (PD-L1) and integrin αvβ6 on the surface of tumor cells. The drug is constructed using Alphamab's proprietary glycan-specific conjugation platform, featuring a single-domain antibody (sdAb) Fc fusion protein conjugated to a topoisomerase I inhibitor payload (T01, also known as Alphatecan) via a cleavable linker. Upon binding to its targets, JSKN022 is internalized via endocytosis, and the payload is released by proteolytic enzymes like cathepsin B to induce tumor cell apoptosis. It is specifically being evaluated for patients with tumors refractory to PD-1/PD-L1 inhibitors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer.